TY - JOUR T1 - Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis JF - medRxiv DO - 10.1101/2020.12.03.20239863 SP - 2020.12.03.20239863 AU - Martin Modrák AU - Paul-Christian Bürkner AU - Tomáš Sieger AU - Tomáš Slisz AU - Martina Vašáková AU - Grigorij Mesežnikov AU - Luis Fernando Casas-Mendez AU - Jaromír Vajter AU - Jan Táborský AU - Viktor Kubricht AU - Daniel Suk AU - Jan Horejsek AU - Martin Jedlička AU - Adriana Mifková AU - Adam Jaroš AU - Miroslav Kubiska AU - Jana Váchalová AU - Robin Šín AU - Markéta Veverková AU - Zbyšek Pospíšil AU - Julie Vohryzková AU - Rebeka Pokrievková AU - Kristián Hrušák AU - Kristína Christozova AU - Vianey Leos-Barajas AU - Karel Fišer AU - Tomáš Hyánek Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/04/2020.12.03.20239863.abstract N2 - We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. Most patients were admitted during the first wave of the epidemic. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid-19 severity showing that they mostly perform unsatisfactorily on our dataset.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by ELIXIR CZ research infrastructure project (MEYS Grant No: LM2018131) including access to computing and storage facilities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical committees of General University Hospital, Hospital Novy Jicin, Motol University Hospital, Thomayer Hospital, University Hospital Vinohrady, Military Hospital Olomouc, Na Homolce Hospital, University Hospital in Pilsen, Horovice Hospital, Jihlava Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, if legal obligations under GDPR can be met. The data are not publicly available due to privacy restrictions. We will be happy to arrange to run any analytical code locally and share the results, provided the code and the results do not leak personal information. ER -